Home > Insider Trading > Filing (0001209191-21-038750)

Filing Details

Accession Number:: 0001209191-21-038750
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-07 18:39:39
Reporting Period:: 2021-06-03

Accepted Time:: 2021-06-07 18:39:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808158	Repare Therapeutics Inc.	RPTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2021-06-03	22,296	$31.92	4,180,278	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2021-06-04	8,042	$30.80	4,172,236	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2021-06-04	4,694	$31.28	4,167,542	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2021-06-07	2,400	$30.74	4,165,142	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2021-06-07	1,700	$32.25	4,163,442	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2021-06-07	19,017	$32.96	4,144,425	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.
The shares were sold as follows: 9,497 by MPM BioVentures 2014, L.P. ("BV 2014"), 327 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 12,472 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.35 to $32.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,163,535 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 74,470 by AM BV2014 and 1,806,430 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were sold as follows: 3,426 by BV 2014, 118 by AM BV2014 and 4,498 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,160,109 by BV 2014, 135,843 by BV 2014(B), 74,352 by AM BV2014 and 1,801,932 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were sold as follows: 1,999 by BV 2014, 69 by AM BV2014 and 2,626 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,158,110 by BV 2014, 135,843 by BV 2014(B), 74,283 by AM BV2014 and 1,799,306 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were sold as follows: 1,023 by BV 2014, 35 by AM BV2014 and 1,342 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.41 to $31.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,157,087 by BV 2014, 135,843 by BV 2014(B), 74,248 by AM BV2014 and 1,797,964 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were sold as follows: 724 by BV 2014, 25 by AM BV2014 and 951 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,156,363 by BV 2014, 135,843 by BV 2014(B), 74,223 by AM BV2014 and 1,797,013 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were sold as follows: 8,100 by BV 2014, 279 by AM BV2014 and 10,638 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,148,263 by BV 2014, 135,843 by BV 2014(B), 73,944 by AM BV2014 and 1,786,375 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.